Supernus Pharmaceuticals Dividends
| SUPN Stock | USD 36.99 0.85 2.35% |
As of the 29th of November 2024, Dividend Paid And Capex Coverage Ratio is likely to grow to 211.69. Supernus Pharmaceuticals' past performance could be the main factor of why investors trade Supernus Pharmaceuticals stock today. Investors should clearly understand every aspect of the Supernus Pharmaceuticals dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Supernus Pharmaceuticals' dividend schedule and payout information. Supernus Pharmaceuticals dividends can also provide a clue to the current valuation of Supernus Pharmaceuticals.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | 201.61 | 211.69 |
Supernus |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Supernus Pharmaceuticals must own a stock before its ex-dividend date to receive its next dividend.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.